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The cytotoxic activity and the chemical composition of the dichloromethane/methanol root extract of Linum scabrellum Planchon
(Linaceae) were analyzed. Using NMR spectra andmass spectrometry analyses of the extract we identified eight main constituents:
oleic acid (1), octadecenoic acid (2), stigmasterol (3), 𝛼-amyrin (4), pinoresinol (5), 6 methoxypodophyllotoxin (6), coniferin
(7), and 6-methoxypodophyllotoxin-7-O-𝛽-D-glucopyranoside (8). By using the sulforhodamine B assay, an important cytotoxic
activity against four human cancer cell lines, HF6 colon (IC
50
= 0.57 𝜇g/mL), MCF7 breast (IC
50
= 0.56 𝜇g/mL), PC3 prostate
(IC
50
= 1.60 𝜇g/mL), and SiHa cervical (IC
50
= 1.54 𝜇g/mL), as well as toward the normal fibroblasts line HFS-30 IC
50
= 1.02 𝜇g/mL
was demonstrated. Compound 6 (6-methoxypodophyllotoxin) was responsible for the cytotoxic activity exhibiting an IC
50
value
range of 0.0632 to 2.7433 𝜇g/mL against the tested cell lines. Cell cycle studies with compound 6 exhibited a cell arrest in G2/M
of the prostate PC3 cancer cell line. Microtubule disruption studies demonstrated that compound 6 inhibited the polymerization
of tubulin through its binding to the colchicine site (binding constant 𝐾
𝑏
= 7.6 × 10
6M−1). A dose-response apoptotic effect was
also observed. This work constitutes the first investigation reporting the chemical composition of L. scabrellum and the first study
determining the mechanism of action of compound 6.
1. Introduction
The genus Linum of the Linaceae family includes more than
200 globally distributed species. The phytochemical profiles
that have been reported for the species of Linum suggest
the presence of some lignan-type secondary metabolites [1].
These kinds of compounds show several important pharma-
cological activities such as transcriptase reverse inhibition
and HIV activity, effects on cardiovascular system, antileish-
maniasis properties, hypoglycemic activities, 5-lipoxygenase
inhibition, and antifungal, antirheumatic, antipsoriasis, anti-
malarial, and antiasthmatic properties [2–14]. However,
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cytotoxic and antitumoral activities are a major interest
on these types of lignans [15]. Podophyllotoxin (PTOX) is
the most important aryltetralin-lignan for human health in
relation to anticancer and antiviral activities. It is used for
the treatment of genital warts (condyloma acuminata) caused
by the human papilloma virus [15] and for the semisynthesis
of the two important antineoplastic agents etoposide and
teniposide, which are actually used in the treatment of several
cancers, among others: acute myeloid leukemia, Hodgkin’s
disease, non-Hodgkin’s lymphoma, lung cancer (both small
cell and non-small cell), gastric cancer, breast cancer, and
ovarian cancer [16].
Some species of Linum as L. persicum and L. nodiflorum
accumulate PTOX [17], while others as L. flavum, L.mucrona-
tum ssp. armenum, L. capitatum, L. arboretum, L. campanu-
latum, L. elegans, L. pamphylicum, L. tauricum, L. thracicum,
L. sibiricum, and L. nodiflorum accumulate 6-methoxypodo-
phyllotoxin (6MPTOX) [18]. The mechanism of action of
PTOX is based on the inhibition of tubulin polymerization
through interaction with the binding site of colchicine [19]
as well as on the arrest of the cell cycle in metaphase [20–
22]. Although the compound 6MPTOX has been reported
with cytotoxic activity against murine Ehrlich ascites and
HeLa cervix uteri neoplastic cell lines, its mechanism of
action is unknown. Others derivatives as desmethoxy-yatein
and desoxypodophyllotoxin are responsible for cytotoxic and
antitumoral activities [23, 24]. The analogue 4󸀠-demethyl-
epipodophyllotoxin inhibits DNA topoisomerase II [16, 24],
and several series of nonlactonic podophyllic aldehyde
analogues produce apoptosis induction of neoplastic cells
without a previous tubulin inhibition [25].
In Mexico 28 species of Linum have been identified, of
which 12 are endemic. The species of Linum are used in
Mexican Traditional Medicine to treat respiratory infections,
snake bites, malaria, leishmaniasis, gastrointestinal affec-
tions, inflammation, and cystitis as well as other conditions
[26–29].
Linum scabrellum is a perennial herb endemic to Mexico
that grows up to 40 or 50 cm, pubescent in its green parts
with leaves alternated and flowering from June to December
[28]. It is distributed in 7 states of the country: Quere´taro,
Guanajuato, Hidalgo, Oaxaca, Puebla, Nuevo Leo´n, and
Tamaulipas. In a previous study, we reported the cytotoxic
activity of three extracts (chloroform, butanol, and aqueous)
prepared from aerial parts and roots of L. scabrellum against
three human cancer cell lines. The obtained results showed
that the most toxic activity was observed from the root’s
chloroformic extract against KB (epidermoid), HF6 (colon),
and MCF7 (breast) carcinomas, exhibiting IC
50
values that
ranged from 0.2 to 4.8 𝜇g/mL [30].
The aim of the present investigation was to study the
chemical composition of Linum scabrellum and to identify
its cytotoxic constituents. This is the first phytochemical
study that reports the complete metabolic content of this
species that allowed the identification of 6MPTOX as the
active metabolite against human cancer cell lines. In order to
explore the mechanism of action of this compound, several
studies were conducted to determine its effects on the cell
cycle progression of PC3 prostate cancer cells, mitotic arrest,
microtubule polymerization, binding affinity to tubulin, and
cell death.
2. Materials and Methods
2.1. Plant Material. The wild plant Linum scabrellum was
collected by M.S. Ivonne Alejandre Garc´ıa on November
2012 at 5 km to the south of Vizarro´n, Cadereyta Queretaro,
Mexico. A sample was authentified by BS Alejandro Flores
and deposited at the HUMO Herbarium of the Universidad
Auto´noma del Estado de Morelos (UAEM), with the voucher
number 27194.
2.2. Preparation of Extracts. The collected plant material was
air dried and grounded using an electricmill (749 g), and four
extracts of L. scabrellum were obtained with solvents of dif-
ferent polarity (hexane, ethyl acetate, dichloromethane, and
methanol). The extracts of dichloromethane and methanol
exhibited the major content of secondary metabolites; non-
polar metabolites were present in the dichloromethane
extract while polar metabolites were in the methanol extract.
The grounded plant was extracted with CH
2
Cl
2
:MeOH
(50/50 v/v), in order to obtain themajority of the compounds,
and sonicated during 30min (×3). The extract was concen-
trated in a Buchi rotary evaporator at 40∘Cand stored at room
temperature for further chemical fractionation. The extract
yield was 19.4 g.
2.3. Isolation of Compounds. Compounds were isolated by
means of open column chromatography (CC). The isolation
procedures and purity of compounds were checked by thin
layer chromatography (TLC), visualized by means of UV
light, and sprayed with Ce(SO
4
)
2
⋅2(NH
4
)
2
SO
4
⋅2H
2
O. The
UV spectra were recorded on a Hewlett Packard 8452A
spectrophotometer. All 1H, 13C, and 2D NMR experiments
were recorded inCDCl
3
, acetone-𝑑
6
, andCD
3
ODon aVarian
Unity 400 spectrometer at 400MHz for 1H NMR, and at
100MHz for 13C NMR. FABMS spectra were recorded on a
JEOL JMX-AX 505 HA mass spectrometer. The IR spectrum
was recorded on a Perkin Elmer FTIR spectrophotometer
(Perkin Elmer, USA) using KBr, measured in cm−1.
Melting points were determined on a Fisher-Johns Melting
Point apparatus. Optical rotations were measured on a
Perkin-Elmer 341 digital polarimeter at 25∘C. All the
reagents and solvents used were of analytical grade. The
CH
2
Cl
2
:MeOH extract (19.4 g) was fractionated in an open
chromatographic column (60 cm × 9 cm) previously packed
with silica gel (582 g, 70–230 mesh; Merck) and eluted with
a dichloromethane/methanol gradient system, starting with
100% of the less polar solvent and subsequently increasing
the methanol. Seventy-eight fractions of 100mL each were
collected and concentrated by vacuum distillation and
grouped according to their chemical content as monitored
by TLC. Eight groups of fractions were obtained: F-1 (1.3 g,
100 : 0), F-2 (2.5 g, 98 : 2), F-3 (1.0 g, 96 : 4), F-4 (1.82 g, 94 : 6),
F-5 (3.71 g, 92 : 8), F-6 (2.88 g, 90 : 10), F-7 (2.75 g, 85 : 15),
and F-8 (0.90 g, 0 : 100). In the less polar fraction (F-1) oleic
acid (1, 180mg) and octadecenoic acid (2, 320mg) were
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identified. After a successive chromatographic process using
CH
2
Cl
2
:MeOH gradient system, F-2 (100 : 00→ 97 : 03)
yielded stigmasterol (3, 25mg) and 𝛼-amyrin (4, 14mg),
F-5 (100 : 00→ 85 : 15) afforded pinoresinol (5, 4.9mg),
6-methoxypodophyllotoxin (6, 40mg), and coniferin
(7, 6.5mg) and F-6 (100 : 00→ 80 : 20) yielded 6-
methoxypodophyllotoxin-7-O-𝛽-D-glucopyranoside (8,
503.1mg).
2.4. Cytotoxic Assay. The CH
2
Cl
2
:MeOH of aerial and root
extracts as well as compounds 6, 7, and 8 were subjected
to a cytotoxic evaluation using breast (MCF7), colon (HF6),
prostate (PC3), and cervical (SiHa) human cancer cell lines
fromATCC (AmericanTypeCulture Collection,USA), along
with normal human fibroblast cells (HSF-30) at passage
number 33 (In Vitro Co.). Cell cultures were grown in
RPMI-1640 medium (Sigma Aldrich) supplemented with
fetal bovine serum 10% (SFB, Invitrogen), NaHCO
3
7.5%, and
cultivated in 96-well plates (104 cells/mL) at 37∘C with CO
2
5% (humidity 100%). Normal human fibroblasts were grown
in DMEM medium (Invitrogen) supplemented with fetal
bovine serum 10%. The cells in a log phase of their growth
cycle were treated in triplicate with various concentrations
of the test samples (0.16–20 𝜇g/mL) dissolved in dimethyl
sulfoxide (DMSO, Sigma Aldrich) and incubated for 72 h in
the conditions described above. In order to guarantee that the
cells were in exponential growth, the criteria of confluence
between 60–70% were adopted. The cell concentration was
determined by the NCI sulforhodamine method [31]. The
results were expressed as the dose that inhibits 50% control
growth after the incubation period (IC
50
). The values were
estimated from a log 10 plot of the drug concentration against
the percentage of viable cells. The standards included as
controlswere PTOXandTaxol (SigmaAldrich). Extractswith
IC
50
≤ 20𝜇g/mL and compounds with IC
50
≤ 4 𝜇g/mL were
considered active according to the National Cancer Institute
(NCI) guidelines [32]. The data analysis was processed using
the program ORIGIN 8.0, IC
50
values were obtained by a
regression curve with coefficient factors 𝑅2 between 0.80 and
0.99.
2.5. Cell Cycle Analysis. Prostate cancer cells PC3 (1 × 105)
were plated in 6-well plates and allowed to attach overnight
at 37∘C in 5%CO
2
. Exponential growing cells were exposed at
four different concentrations of 6MPTOX in accordance with
IC
50
values (0.011𝜇M, 0.005 𝜇M, 0.002 𝜇M, and 0.001𝜇M)
for 72 h. Cells from each treatment were trypsinized and
collected into single cell suspensions, centrifuged, and fixed
in cold ethanol (70%) overnight at −20∘C.The cells were then
treated with RNase (0.01M, Sigma Aldrich) and stained with
propidium iodide (PI) (7.5 𝜇g/mL, Invitrogen) for 30min in
the dark, PI has the ability to bind to DNA molecules, and
then RNase was added in order to allow PI to bind directly
to DNA. The percentage of cells in G1, S, and G2 phases
was analyzed with a flow cytometer (Becton, Dickinson,
FACS Calibur, San Jose, CA); the number of cells analyzed
for each sample was 10,000. Data obtained from the flow
cytometer were analyzed using the FlowJo Software (Tree
Star, Inc., Ashland, OR, USA) to generate DNA content
frequency histograms, and to quantify the number of cells in
the individual cell cycle phases.
2.6. Immunofluorescence of Histone H3 Phosphorylated. PC3
cells were grown in RPMI medium, and 7.5 × 104 cells were
added in 24-well culture plates containing slides and allowed
to attach overnight at 37∘C in 5% CO
2
. Then, they were
treated with 6MPTOX (0.005𝜇M), PTOX (0.002𝜇M), and
DMSO (2.25 𝜇M) at 37∘C for 72 h. The cells were fixed with
PFA (p-formaldehyde) 4% in PEM buffer PIPES (0.1M),
EGTA (2mM), and MgSO
4
(1mM), pH 6.95. After 15min
PFA/NaHCO
3
was added and incubated for 45min at room
temperature. The slides were rinsed with PBS, treated with
0.1% Triton X-100 (Sigma Aldrich), and then incubated with
the primary antibody antiphospho-histone H3 (1 : 500, Santa
Cruz Biotechnology) overnight at 4∘C. A secondary antibody
anti-rabbit Alexa 488 (1 : 1000, Molecular Probes) was added
and incubated for 1 h at 37∘C. The cells were stained with
0.4 𝜇g/mL 4,6-diamidino-2-phenylindole (DAPI, Molecular
Probes, Eugene, OR) in PBS for 10min, then mounted, and
imaged by fluorescence microscopy.
2.7. Immunofluorescence of 𝛼-Tubulin. PC3 cells were grown
in RPMI medium, and 7.5 × 104 cells were added in 24-
well culture plates containing slides and allowed to attach
overnight at 37∘C in 5% CO
2
. Then they were treated
with 6MPTOX (0.005𝜇M), PTOX (0.002𝜇M), and DMSO
(2.25 𝜇M-0.02%) at 37∘C for 72 h. The cells were fixed with
PFA (paraformaldehyde) 4% in PEM (buffer). After 15min
PFA/NaHCO
3
was added and incubated for 45min at room
temperature. The slides were rinsed with PBS and treated
with 0.1% Triton X-100 (Sigma Aldrich) and then incubated
with the first antibody anti-𝛼-tubulin (1 : 300, Sigma Aldrich)
overnight at 4∘C. A second antibody anti-mouse Alexa 647
(1 : 1000, Molecular Probes) was added and incubated for
two hours at 37∘C. The cells were stained with Sytox Green
(1 : 5000) for one hour, mounted, and imaged by confocal
microscopy.
2.8. Determination of the Binding Site and Affinity Constant
𝐾
𝑏
. The binding affinity constant (𝐾
𝑏
) of 6MPTOX was
determined following the method described previously [33].
Displacement of the colchicine analogue MTC [2-methoxy-
5-(2,3,4-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one], a
commercial reversible tubulin ligand in the colchicine site
that binds to the heterodimer 𝛼/𝛽 tubulin, was evaluated.
Initially,mixtures of tubulin andMTC (5𝜇M)were incubated
in 10mM of buffer GAB (NaPi with 0.1mM GTP and pH
7). Subsequently, increasing concentrations of the above
tested compound and controls were added and incubated
for 10min between each concentration at 25∘C in the
fluorometer Horiba Fluoromax-2, with 𝜆 exc = 350 nm and
𝜆 em = 423 nm. Binding constants were calculated by the
decrease of the fluorescence of MTC due to competition
for the same site. Data processing was analyzed using the
Equigra v5 software [34].
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Table 1: IC50 values (𝜇g/mL) of dichloromethane/methanol extract and 6MPTOX isolated from Linum scabrellum.
Extract/compound Cell lines
PC3 MCF7 HF6 SiHa HFS-30
CH2Cl2:MeOH extract 1.60 ± 0.07 5.7 × 10
−1
± 0.07 5.7 × 10−1 ± 0.07 1.54 ± 0.07 1.02 ± 0.07
6MPTOX 1.7 × 10−1 ± 0.07 6.6 × 10−2 ± 0.07 7.9 × 10−2 ± 0.07 2.74 ± 0.07 6.0 × 10−2 ± 0.07
PTOX 3 × 10−3 ± 0.07 1 × 10−4 ± 0.07 1.4 × 10−3 ± 0.07 1.23 ± 0.07 1 × 10−4 ± 0.07
Taxol 6.2 × 10−1 ± 0.07 1.3 × 10−1 ± 0.07 2.8 × 10−1 ± 0.07 2.30 ± 0.07 1.2 × 10−1 ± 0.07
PC3: prostate cancer, MCF7: breast cancer, HF6: colon cancer, SiHa: cervical cancer, and HFS-30: fibroblasts.
2.9. Cell Death. PC3 cells (7.5 × 104 cells/mL) were seeded
in 6-well plates and incubated for 18 h. Exponentially grow-
ing cells were treated for 72 h with RPMI medium added
with 0.02% of DMSO (control) and with four different
concentrations of 6MPTOX (0.011𝜇M, 0.005 𝜇M, 0.002 𝜇M,
and 0.001𝜇M) in accordance with the IC
50
value of the
compound. Cells treated with H
2
O
2
were used as apoptotic
death control [35] and for the necrotic control PC3 cells
were treated with boiling water. Then, each cell culture
was washed with 100mL of PBS and stained with 100 𝜇L
AO/EB solution (100 𝜇g/mL AO, 100𝜇g/mL EB), according
to reported procedures [36]. The cells were observed using a
fluorescence microscope (Olympus Co., Tokyo, Japan, with
emission at 521 nm). AO/EB are intercalating nucleic acid-
specific fluorochromes, andwhen bounded toDNA they emit
green and orange fluorescence, respectively. It is well known
that AO can pass through cell membranes, but EB cannot.
Under the fluorescence microscope, living cells appear green.
Necrotic cells stain red but have a nuclear morphology
resembling that of viable cells. Apoptotic cells appear green,
and morphological changes such as formation of apoptotic
bodies are observed. The criteria for identification are as
follows: (i) viable cells appear to have green nucleus with
intact structure; (ii) early apoptosis cells exhibit a bright-
green nucleus showing condensation of chromatin; (iii) late
apoptosis appears as dense orange areas of chromatin con-
densation; and (iv) orange intact nucleus depicts secondary
necrosis [37].
3. Results and Discussion
3.1. Cytotoxic Activity and Chemical Composition of Linum
scabrellum. TheCH
2
Cl
2
:MeOH extract from aerial parts was
noncytotoxic to the tested cell lines (IC
50
≤ 20𝜇g/mL). The
CH
2
Cl
2
:MeOH roots extract of L. scabrellum presented cyto-
toxic activity against the four carcinoma cell lines exhibiting
IC
50
values from 0.56 to 1.54 𝜇g/mL as well as toward the
normal cell line with an IC
50
value of 1.02 𝜇g/mL (Table 1).
The first complete phytochemical profile of L. scabrellum was
established in order to identify the cytotoxic metabolites. In
the CH
2
Cl
2
:MeOH extract, eight compounds were identified
and characterized (Figure 1), three of them (5, 6, and 8)
belong to the lignan group. Four compounds, oleic acid (1),
octadecenoic acid (2) stigmasterol (3), and 𝛼-amyrin (4),
were identified by their spectroscopic data 1H and 13C and
cochromatography with authentic samples available on our
laboratory. The other four compounds were identified by
their spectroscopic data 1H, 13CNMR, spectramass, mp, UV,
IR, and 2D experiments (COSY, HSQC) as follows: F-5 was
subjected to column chromatography packed with silica gel
(115 g) and eluted with a gradient system of CH
2
Cl
2
:MeOH
(100 : 00→ 90 : 10) obtaining 46 fractions of 25mL each and
were grouped in six groups according to their similarity in
thin layer chromatography (F-5A→ F-5F).
Fraction F-5B eluted with 98:02 CH
2
Cl
2
:MeOH afforded
4.9mg of pinoresinol (5), isolated as amorphous powder, mp
121–22∘C (lit: 122∘C) an optically active powder [𝛼]24D −82.3
∘
(c 0.012, Me
2
CO), and had the formula C
20
H
22
O
6
derived
from its positive FABMS [M+H]+ ion at m/z 359. IR (KBr,
𝜐max in cm
−1): 3210, 2870, 1600, 1465 1050.UV𝜆max (nm): 232,
and 280. 1H NMR (400MHz, CDCl
3
) 𝛿H: 6.89 (d, J = 1.2Hz;
H-2, H-2󸀠), 6.88 (d, J = 8.4Hz; H-5, H-5󸀠), 6.81 (dd, J = 2.1
and 8.4Hz; H-6, H-6󸀠), 4.73 (d, J = 4.2Hz; H-7, H-7󸀠), 3.09 (c,
H-8, H-8󸀠), 4.24 (dd, J = 7 and 9.1Hz; 9-H𝛽, 9󸀠-H𝛽), 3.87 (dd,
J = 3.5 and 9.1Hz; 9-H𝛼, 9󸀠-H𝛼), 3.90 (s, C3󸀠-OMe, C3-OMe).
13CNMR (100MHz, CDCl
3
) 𝛿C: 132.90 (C-1, C-1
󸀠), 108.57 (C-
2, C-2󸀠), 146.68 (C-3, C-3󸀠), 145.22 (C-4, C-4󸀠), 114.24 (C-5,
C-5󸀠), 118.96 (C-6, C-6󸀠), 85.86 (C-7, C-7󸀠), 54.16 (C-8, C-8󸀠),
71.66 (C-9, C-9󸀠). On the basis of the spectral data, compound
5 was identified as (-)-pinoresinol [38].
One of the fractions F-5C eluted with 96:04
CH
2
Cl
2
:MeOH yielded 40mg of compound 6, obtained as
a white amorphous powder, mp 202-203∘C (lit: 203∘C). The
positive FABMS spectrum showed the [M + H]+ ion peak
at m/z 445 with molecular formula C
23
H
24
O
9.
IR (KBr, 𝜐max
in cm−1): 3220, 1768, 1600. UV 𝜆max (nm): 272, and 282.
1H
NMR (400MHz, acetone-d
6
) 𝛿H: 6.30 (s, H-3), 5.03 (d, J
= 9.8Hz, H-7), 2.88 (m, H-8), 4.06 (dd, J = 8.4 and 10Hz;
H-9𝛽), 4.64 (t, J = 7.7 and 8.4Hz; H-9𝛼), 6.44 (s, H-2󸀠, H-6󸀠),
4.53 (d, 𝐽 = 4.9Hz, H-7󸀠), 2.75 (dd, 𝐽 = 4.2 and 14.7Hz;
H-8󸀠), 3.78 (s, C3󸀠-OMe, C5󸀠-OMe), 3.81 (s, C4󸀠-OMe), 3.78
(s, C6-OMe), 5.95 (s, –O-CH
2
-O-). 13C NMR (100MHz,
acetone-d
6
) 𝛿C: 124.93 (C-1), 137.04 (C-2), 104.36 (C-3),
149.45 (C-4), 132.84 (C-5), 141.57 (C-6), 70.52 (C-7), 39.01
(C-8), 71.92 (C-9), 134.71 (C-1󸀠), 108.09 (C-2󸀠), 152.61 (C-3󸀠),
134.93 (C-4󸀠), 152.61 C-5󸀠), 108.09 (C-6󸀠), 45.11 (C-7󸀠), 44.53
(C-8󸀠), 174.44 (C-9󸀠), 56.18 (C3󸀠-OMe), 60.77 (C4󸀠-OMe),
56.18 (C5󸀠-OMe), 59.93 (C6-OMe), 101.37 (-O-CH2-O-). On
the basis of the spectral data, compound 6 was identified as
6-methoxypodophyllotoxin [39].
Fraction F-5C eluted with 90 : 10 CH
2
Cl
2
:MeOH yielded
6.5mg of coniferin (7), obtained as an amorphous solid, mp
180–82∘C [lit: 182∘C]. Positive FABMSm/z 342 [M+H]+, with
molecular formula C
16
H
22
O
8
. IR (KBr, 𝜐max in cm
−1): 3020,
Evidence-Based Complementary and Alternative Medicine 5
HO
O
(2)
(1)
OH
O
HO
(3)
HO
(4)
(5)
O
O
OMe
OH
MeO
HO
1
2
4 6
7
8
9
4󳰀
1󳰀
7󳰀
8󳰀
9󳰀
(7)
MeO
OH
OH
OH
HO
HO
O
O
1
2 4
1󳰀
1󳰀󳰀3󳰀󳰀
3󳰀
6󳰀󳰀
OMe
OMeMeO
O
O
O
O
OROMe
1
3
6
7 8
9
1󳰀
4󳰀
3󳰀
7󳰀 8
󳰀
9󳰀
R
(6) H
(8) –𝛽-D-Glucoside
Figure 1: Chemical structure of Linum scabrellum secondary metabolites.
1060, 940. UV 𝜆max (nm): 256 and 292. [𝛼]
24
D −66.3 (c 0.010,
Me
2
CO). 1H NMR (400MHz, CDCl
3
) 𝛿H: 7.07 (d, J=2.4Hz;
H-3), 6.89 (dd, J = 1.6 and 8Hz; H-5), 7.09 (d, J = 8Hz; H-
6), 6.52 (d, J = 15.2Hz; H-1󸀠), 6.29 (td, J = 5.6 and 16Hz; H-
2󸀠), 4.19 (t, J = 5.6Hz; H-3󸀠), 4.87 (d, J = 7.7Hz; H-1󸀠󸀠), 4.23
(t, J = 7.8Hz, H-2󸀠󸀠), 4.22 (t, J = 7.6Hz, H-3󸀠󸀠), 4.21 (dd, J =
7.6 and 7.8Hz, H-4󸀠󸀠), 4.05 (m, H-5󸀠󸀠), 3.54 (t, J = 9.6Hz, H-
6󸀠󸀠a), 3.70 (dd, J = 4.5 and 9.8Hz, H-6󸀠󸀠b), 3.79 (s, C2-OMe).
13C NMR (100MHz, acetone-d
6
) 𝛿C: 150.01 (C-1), 146.54 (C-
2), 110.24 (C-3), 132.36 (C-4), 117.11 (C-5), 119.23 (C-6), 128.88
(C-1󸀠), 128.87 (C-2󸀠), 62.36 (C-3󸀠), 55.53 (C2-OMe), 101.69 (C-
1󸀠󸀠), 73.92 (C-2󸀠󸀠), 77.07 (C-3󸀠󸀠), 70.69 (C-4󸀠󸀠), 76.93 (C-5󸀠󸀠),
61.82 (C-6󸀠󸀠). On the basis of spectral data, compound 7 was
identified as phenylpropane glycoside coniferin (7) [40].
From the fraction F-6, compound 8 was isolated as an
amorphous yellow solid, mp 287∘C [lit: 287∘C]. The positive
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FABMS spectrum showed the [M + H]+ ion peak atm/z 607,
with molecular formula C
29
H
34
O
14.
IR (KBr, 𝜐max in cm
−1):
3020, 1746, 1620, 1050, 920. UV 𝜆max (nm): 276 and 284.
1H
NMR (400MHz, CD
3
OD) 𝛿H: 6.28 (s, H-1), 5.48 (d, 7.2Hz;
H-7), 2.90 (m, H-8), 4.23 (t, J = 8.8 and 9.6Hz; H-9𝛽), 4.71
(t, J = 8.4 and 8.6Hz; H-9𝛼), 6.31 (s, H-2󸀠, H-6󸀠), 4.51 (d, J =
4.8Hz; H-7󸀠), 3.25 (dd, J = 4.8 and 14Hz; H-8󸀠), 3.72 (s, C3󸀠-
OMe, C5󸀠-OMe), 3.99 (s, C4󸀠-OMe), 3.68 (s, C6-OMe), 6.02
(s,-O-CH2-O-), 4.54 (d, J = 7.6Hz; H-1󸀠󸀠), 3.28 (t, J = 9.2Hz;
H-2󸀠󸀠), 3.35 (t, J= 7.2Hz; H-3󸀠󸀠), 3.41 (dd, J = 7.2 y 6.8Hz;
H-4󸀠󸀠), 3.43 (m, H-5󸀠󸀠), 3.76 (dd, J = 2.2 and 10Hz, H-6󸀠󸀠a),
3.84 (dd, J = 5.4 and 10.2Hz, H-6󸀠󸀠b). 13C NMR (100MHz,
CD
3
OD) 𝛿C: 124.26 (C-1), 136.28 (C-2), 105.74 (C-3), 149.68
(C-4), 135.89 (C-5), 140.26 (C-6), 72.78 (C-7), 39.87 (C-8),
72.39 (C-9), 136.73 (C-1󸀠), 108.58 (C-2󸀠), 152.89 (C-3󸀠), 136.54
(C-4󸀠), 152.89 (C-5󸀠), 108.58 (C-6󸀠), 45.86 (C-7󸀠), 46.23 (C-8󸀠),
176.67 (C-9󸀠), 56.24 (C3󸀠-OMe, C5󸀠-OMe), 60.76 (C4󸀠-OMe),
60.76 (C6-OMe), 102.34 (-O-CH2-O-), 100.46 (C-1󸀠󸀠), 74.87
(C-2󸀠󸀠), 77.85 (C-3󸀠󸀠), 71.67 (C-4󸀠󸀠), 78.13 (C-5󸀠󸀠), 63.08 (C-6󸀠󸀠).
On the basis of spectral data, compound 8 was identified as
6-methoxypodophyllotoxin 7-O-𝛽-D-glucopyranoside [40].
The obtained data were compared with the literature
[41–43] (see Supplementary Material Figures 1–6 in Sup-
plementary Material available online at http://dx.doi.org/
10.1155/2015/298463).
Some studies reported that compounds 1, 2, and 4
possess anti-inflammatory activity [42] while compound 5
has chemopreventive properties. [38]. Even though all of the
8 compounds had been previously reported in members of
the genus Linum [44–47], this is the first time that they were
identified in Linum scabrellum.
3.2. Cytotoxic Activity of Purified Compounds. The isolated
compounds 6, 7, and 8 were evaluated for cytotoxic effect
against the above mentioned cell lines. Compounds 7 and
8 were nonactive (IC
50
≥ 20𝜇g/mL), while compound 6
(6MPTOX) showed an important cytotoxic activity with
IC
50
values ranging from 0.0632 to 2.7433 𝜇g/mL against the
cancer tested cell lines (Table 1). It is important to point out
that 6MPTOX was also toxic against the normal fibroblasts.
These data showed that the inhibitory effect of 6MPTOX as
well as that of the CH
2
Cl
2
:MeOH roots extract of Linum
scabrellum is not specific against certain carcinomas but
rather exerts a general cell toxic action. Because the important
cytotoxic activity demonstrated by 6MPTOX, we decided to
investigate the mechanism of action of this compound.
3.3. Effect of 6MPTOX on PC3 Cell Cycle Arrest. The effect
of 6MPTOX in the cell cycle progression of PC3 cells
was determined at four concentrations: 0.011𝜇M, 0.005 𝜇M,
0.002 𝜇M, and 0.001𝜇M.DMSO (2.55 𝜇M-0.02%) and PTOX
(0.0024𝜇M) were used as negative and positive controls,
respectively. Figure 2 displays DNA histograms of PC3 cell
cycle. The 6MPTOX induced in PC3 a G2/M phase cell
arrest. The effect was dose-dependent since cell arrest in
G2/M was declining, while the G1 phase cell population
was increasing when the 6MPTOX concentration decreased.
6MPTOX and PTOX at 0.0002𝜇M induced a similar effect
on G2/M cell arrest with 39.8% and 41.1% of G2/M cell
population, respectively. These results suggest that 6MPTOX
efficiently arrest cells at G2/M phase.
3.4. Effect of 6MOTX onMitotic Arrest. HistoneH3 phospho-
rylated at serine 10 has long been used to identify mitotic
cells nuclei in culture cell lines [48]. The proportion of
cells exhibiting mitosis in the PC3 cultures was determined
using an antibody antiphospho-histone H3, after treatment
with 6MPTOX. The mitotic index was calculated by image
analysis. Taxol and PTOX were used as positive controls,
while DMSO was used as the negative control. 6MPTOX
showed a mitotic index of 0.1, Taxol of 0.25, and PTOX of
0.2, while the negative control displayed a mitotic index of
0.035 (Figure 3).These results suggest that 6MPTOX induces
mitotic arrest as did PTOX and Taxol, in contrast to the
negative control. Inhibition of tubulin has been implicated
in G2/M phase of the cell cycle arrest in various cancer cell
lines [49]. It is well known that Taxol stabilizes microtubules
protecting them from depolymerization, which blocks cells
in mitosis and induces apoptosis [50], in contrast with
PTOX, which promotes depolymerization by destabilizing
microtubules and arrests the cell cycle in mitosis [51].
Our results showed that 6MPTOX induced a mitotic cell
arrest by the observed high mitotic index and the G2/M
cell arrest, suggesting a similar effect as that displayed by
PTOX or Taxol. In order to determine the mechanism of
action of 6MPTOX, we analyzed the effect of microtubule
polymerization by 6MPTOX through disruption of 𝛼/𝛽
tubulin binding.
3.5. Effect of 6MPTOX on the 𝛼-Tubulin Polymerization.
Microtubules are in dynamic equilibriumwith tubulin dimers
as tubulin is polymerized into microtubules and depolymer-
ized as free tubulin. This dynamic equilibrium is targeted
by microtubule disrupting agents [52], which inhibit the
organization of the mitotic spindle and arrest chromosomes
in metaphase of mitosis [53]. The effect of 6MPTOX on the
microtubule polymerization by immunofluorescence of 𝛼-
tubulin was observed in PC3 cells by confocal microscopy.
Figure 4(b) shows that treatment with 6MPTOX inhibits the
polymerization of microtubules possibly through binding to
tubulin, of which effect was also observed by treatment with
PTOX (Figure 4(c)). In the negative control (DMSO 0.02%,
Figure 4(a)) no effect was appreciated.
These results suggest that 6MPTOX as well as PTOX act
as microtubule-destabilizing agents, while cells treated with
DMSO (0.02%) demonstrated a normal and intact tubulin
organization (Figure 4(a)).
3.6. Determination of the Binding Site and Binding Constant
(𝐾
𝑏
) of 6MPTOX. To corroborate whether 6MPTOX binds
to 𝛼/𝛽-tubulin as does PTOX, 6MPTOX was assayed for its
ability to displace MTC from its binding at the colchicine site
of 𝛼/𝛽-tubulin [54, 55]. Figure 5 shows fluorescence changes
produced by the displacement of MTC binding to tubulin by
both 6MPTOX and PTOX.The fluorescence spectra of MTC
decreased by 43% with 6MPTOX indicating that 6MPTOX
binds to the colchicine binding site, while PTOX decreased
65%. The binding constant for 6MPTOX was determined
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Figure 2: Effect of 6MPTOX on cell cycle in the prostate PC3 cell line. (a) Negative control with DMSO 0.02%; (b) PC3 cells exposed to
0.002 𝜇MPTOX as positive control; (c–f) PC3 cells exposed to different concentrations of 6MPTOX; (c) 0.011 𝜇M; (d) 0.005 𝜇M; (e) 0.002 𝜇M;
(f) 0.001 𝜇M.
as 𝐾
𝑏
= 7.26 × 106M−1 by displacement of MTC in the
colchicine binding site. MTC has 𝐾
𝑏
= 4.7 × 105M−1 [33],
which indicated that 6MPTOX is a stronger inhibitor when
compared to MTC.
3.7. Effect of 6MPTOX on Cellular Death of PC3 Cells. Cell
death occurs through at least three morphologically distinct
subroutines that have been named apoptosis, autophagy
cell death (ACD), and necrosis [56]. Apoptosis is morpho-
logically defined by nuclear shrinkage and fragmentation
[57], whereas necrosis is defined by early permeabilization
of the plasma membrane [58]. The effect of 6MPTOX on
cellular death of prostate cancer cells was determined using
four different concentrations. The compound 6MPTOX at
a lower concentration of 0.001𝜇M did not show any effect
on cell death. When the concentration was increased to
0.002 𝜇Msome apoptotic bodies were observed (Figure 6(e));
with 0.005𝜇M, few cells were in late apoptosis and others
were necrotic (orange or red color, Figure 6(f)); and at the
highest concentration of 0.011 𝜇M the effect caused cell death
mainly by necrosis (Figure 6(g)). Three controls were used:
boiling water for necrosis, where most of the cells stained
in red (Figure 6(c)); H
2
O
2
for apoptosis, where some of
the cells stained in green or orange with apoptotic bodies
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Figure 3: Effect of 6MPTOX on mitosis of the prostate cancer cell line PC3.
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Figure 4: Effect of microtubules polymerization. (a) DMSO 0.02%, (b) 6MPTOX, and (c) PTOX.
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Figure 5: Displacement of MTC by 6MPTOX measured with fluorescence, (a) MTC with tubulin, (b) 6MPTOX, (c) PTOX, and (d) MTC.
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Figure 6: Effect of 6MPTOX on the prostate cancer cells (PC3). (a) Negative control; (b) apoptosis control; (c) necrosis control; (d–g) cells
exposed to different concentrations of 6MPTOX; (d) 0.001 𝜇M; (e) 0.002 𝜇M; (f) 0.005 𝜇M; (6) 0.011 𝜇M.The arrow points out the cells that
were amplified (40x). (b) Apoptotic cells; (c) necrotic cells; (e) apoptotic cells (0.002𝜇M); (f) late apoptosis (0.005 𝜇M); (g) necrotic cells
(0.011𝜇M).
(Figure 6(b)), and a negative control with most of the cells
stained in green (cells without treatment, Figure 6(a)). The
effect of 6MPTOXonprostate cancer cells was dose-response,
inducing apoptosis followed by necrosis when the concentra-
tion increased.
4. Conclusion
For the first time, the metabolic content of the Mexican
species L. scabrellum was established. Eight compounds
including lignans, terpenes, and fatty acids were isolated
and identified. This study demonstrated the cytotoxic activ-
ity of 6MPTOX toward four selected human carcinomas
and against a normal fibroblast cell line. Biochemical and
biological experiments showed that 6MPTOX specifically
arrested PC3 cells in their G2/M phase as well as a higher
mitotic index.Moreover, at its lowest concentration it induces
apoptosis as shown by an increase in its subG1 cell popula-
tion and in stained apoptotic cells. Necrotic cell death was
observed at higher concentrations. Data presented in this
study show that 6MPTOX binds at the colchicine binding site
of tubulin with a 𝐾
𝑏
= 7.26 × 106M−1, causing disruption of
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tubulin polymerization. These results showed that 6MPTOX
inhibit tubulin polymerization and arrest cells in G2/M as a
mechanism of cytotoxic activity in PC3 cells. This is the first
report describing the mechanism of action of 6MPTOX.
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